Abu Dhabi’s Mubadala Investment Company, through its unit Kelix Bio, has finalized the acquisition of DiabTec, a subsidiary of Julphar. This move marks a significant step in strengthening Mubadala’s biologicals portfolio and advancing biomanufacturing in the MENA region. DiabTec’s advanced facility, equipped with 20,000-litre drug substance reactors and a dedicated cartridge fill-finish facility for drug...
